We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

51 hedge funds and large institutions have $9.31M invested in Matinas BioPharma in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

2% more funds holding

Funds holding: 50 → 51 (+1)

0.01% less ownership

Funds ownership: 0.25% → 0.24% (-0.01%)

26% less capital invested

Capital invested by funds: $12.6M → $9.31M (-$3.29M)

57% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 14

Holders
51
Holders Change
+1
Holders Change %
+2%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
14
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
+$261K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$71.9K
3
VF
Virtu Financial
New York
+$42.1K
4
BlackRock
BlackRock
New York
+$18.5K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$9.35K

Top Sellers

Rank Fund Capital Flow
1
NRS
Neville Rodie & Shaw
New York
-$278K
2
BCM
Bridgeway Capital Management
Texas
-$166K
3
SIG
Sargent Investment Group
Maryland
-$153K
4
Millennium Management
Millennium Management
New York
-$90.5K
5
Jane Street
Jane Street
New York
-$27.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
GRP
26
Global Retirement Partners
California
$18K -$23.3K -1,000 -50%
Commonwealth Equity Services
27
Commonwealth Equity Services
Massachusetts
$18K +$9.35K +401 +69%
JP Morgan Chase
28
JP Morgan Chase
New York
$16.2K – – –
NWMG
29
National Wealth Management Group
Ohio
$14.5K +$1.28K +55 +7%
AWS
30
Atria Wealth Solutions
New York
$14.2K – – –
Morgan Stanley
31
Morgan Stanley
New York
$10.8K -$3.38K -145 -19%
DAS
32
Dynamic Advisor Solutions
Arizona
$9.93K – – –
Millennium Management
33
Millennium Management
New York
$6.4K -$90.5K -3,883 -92%
RPC
34
Rossmore Private Capital
Connecticut
$6.3K – – –
UBS Group
35
UBS Group
Switzerland
$5.15K +$6.67K +286 New
CFG
36
Cooper Financial Group
California
$5K – – –
Osaic Holdings
37
Osaic Holdings
Arizona
$4.68K -$560 -24 -8%
CG
38
Clarus Group
Texas
$4.32K – – –
SW
39
SlateStone Wealth
Florida
$4K – – –
JWCA
40
J.W. Cole Advisors
Florida
$3.87K – – –
CFS
41
CRA Financial Services
New Jersey
$3.6K – – –
MFG
42
Magnus Financial Group
New York
$3.6K – – –
BBA
43
Baader Bank Aktiengesellschaft
Germany
$3.5K +$5.85K +251 New
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$3K -$210 -9 -6%
HF
45
HRT Financial
New York
$3K +$4.78K +205 New
TRCT
46
Tower Research Capital (TRC)
New York
$2.88K -$6.18K -265 -62%
SPIA
47
Steward Partners Investment Advisory
New York
$1.09K – – –
EWA
48
EverSource Wealth Advisors
Alabama
$1.08K – – –
HFM
49
Hartford Financial Management
Connecticut
$900 – – –
GWMIA
50
Global Wealth Management Investment Advisory
Florida
$234 +$303 +13 New
1
2
3

MTNB Hedge Fund Activity: Q2 2023 in Review

51 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2023, worth a combined $9.31M — down 26% from $12.6M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new MTNB positions and 4 closed out — a net gain of 1 holder — while 6 added to existing stakes and 14 trimmed.

The largest buyer was Wells Fargo, adding an estimated $261K. The largest seller was Neville Rodie & Shaw, cutting an estimated $278K.

  • 51 institutional investors held Matinas BioPharma (MTNB) as of Q2 2023, up from 50 in Q1 2023.
  • Funds reported $9.31M of Matinas BioPharma stock for Q2 2023, down 26% quarter-over-quarter.
  • 5 funds opened new Matinas BioPharma positions in Q2 2023 and 4 closed out, a net change of +1 holder.
  • The largest Matinas BioPharma buyer in Q2 2023 was Wells Fargo, an estimated $261K added.
  • The largest Matinas BioPharma seller in Q2 2023 was Neville Rodie & Shaw, an estimated $278K sold.

Based on aggregated 13F filings for Q2 2023.